Rapid Microwave-Assisted Syntheses of Derivatives of HIV-1 Entry Inhibitors
作者:David A. Vicic、Asim Kumar Debnath、Chris McFarland
DOI:10.1055/s-2006-926339
日期:——
The direct amidation of esters with 4-amino-2,2,6,6-tetramethylpiperidine was achieved by computer-controlled microwave irradiation in toluene. The microwave protocol allowed the new amides to be prepared in three hours rather than the three days required by traditional thermal methods.
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening
作者:Judith M. LaLonde、Mark A. Elban、Joel R. Courter、Akihiro Sugawara、Takahiro Soeta、Navid Madani、Amy M. Princiotto、Young Do Kwon、Peter D. Kwong、Arne Schön、Ernesto Freire、Joseph Sodroski、Amos B. Smith
DOI:10.1016/j.bmc.2010.11.049
日期:2011.1
The low-molecular-weight compound JRC-II-191 inhibits infection of HIV-1 by blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor and is therefore an important lead in the development of a potent viral entry inhibitor. Reported here is the use of two orthogonal screening methods, GOLD docking and ROCS shape-based similarity searching, to identify amine-building blocks that, when conjugated to the core scaffold, yield novel analogs that maintain similar affinity for gp120. Use of this computational approach to expand SAR produced analogs of equal inhibitory activity but with diverse capacity to enhance viral infection. The novel analogs provide additional lead scaffolds for the development of HIV-1 entry inhibitors that employ protein-ligand interactions in the vestibule of gp120 Phe 43 cavity. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR UNE CANCÉROTHÉRAPIE SÉLECTIVE ET CIBLÉE
申请人:UNIV TEXAS
公开号:WO2015035051A1
公开(公告)日:2015-03-12
Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.